Curis (CRIS) Expected to Announce Quarterly Earnings on Tuesday

Curis (NASDAQ:CRIS) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Curis to post earnings of ($5.80) per share and revenue of $1.00 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). On average, analysts expect Curis to post $-26 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Curis Stock Performance

Shares of NASDAQ:CRIS opened at $4.72 on Tuesday. Curis has a 52-week low of $3.61 and a 52-week high of $39.00. The company has a market capitalization of $9.21 million, a P/E ratio of -0.20 and a beta of 3.08. The company has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $13.11.

Institutional Investors Weigh In On Curis

Several hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC boosted its holdings in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares during the period. XTX Topco Ltd bought a new position in shares of Curis during the fourth quarter worth approximately $26,000. Squarepoint Ops LLC lifted its holdings in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Curis by 37.3% in the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRIS has been the topic of several research analyst reports. Zacks Research upgraded Curis from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reiterated a “buy” rating and set a $43.00 target price (up from $17.00) on shares of Curis in a research note on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $43.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.